专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明授权

US4274949A Froth separation apparatus 失效
标题翻译：泡沫分离装置
公开(公告)号：US4274949A
公开(公告)日：1981-06-23
申请号：US78591
申请日：1979-09-24
申请人： James R. McCarthy
发明人： James R. McCarthy
IPC分类号： B03B7/00 , B03D1/14
CPC分类号： B03B7/00 , B03D1/1462 , B03D1/1481
摘要： A froth separation apparatus is provided having a separation container of generally rectangular form having two spaced generally parallel vertical sides, two generally parallel ends and a bottom, an influent feed delivering a suspension of solids in liquid at spaced points along the top of the separation container, a reagent inlet into the influent feed in advance of the separation container, diagonal froth retention screen means extending across the separation container from end to end and from a line intermediate the top and bottom of one side wall to a line adjacent the bottom of the other side wall, froth creating means in the separation container above said screen means, a weir discharge means on the said other side wall at the bottom thereof adjacent the screen means line for removal of froth and outlet means at the bottom of said one side for tailings discharge.
摘要翻译：提供了一种泡沫分离装置，其具有大致矩形形式的分离容器，其具有两个间隔开的大致平行的垂直侧面，两个大致平行的端部和底部，流入物料沿着分离容器的顶部的间隔点输送固体在液体中的悬浮液，在分离容器之前进入进水进料器的试剂入口，对角起泡保留筛网装置，其从一端到另一端延伸穿过分离容器，并且从一侧壁的顶部和底部延伸到邻近底部的管线在所述筛网装置上方的分离容器中的另一侧壁，泡沫产生装置，在邻近筛网装置线的底部的所述另一侧壁上的堰排放装置，用于在所述一侧的底部移除泡沫和出口装置，尾矿排放。

52. 发明授权

US4189444A Process for the preparation of N,N'-disubstituted 2-naphthaleneethanimidamide and intermediates used therein 失效
标题翻译：制备N，N'-二取代的2-萘甲酰胺和其中使用的中间体的方法
公开(公告)号：US4189444A
公开(公告)日：1980-02-19
申请号：US6143
申请日：1979-01-24
申请人： Albert Schuster , James R. McCarthy
发明人： Albert Schuster , James R. McCarthy
IPC分类号： C07C119/18
摘要： N,N.fwdarw.-disubstituted 2-naphthaleneethanimidamide is prepared by the conversion of a nitrile into the novel imido ester salt intermediate by alcoholysis followed by treatment of the intermediate with an alkylamine to give the product.
摘要翻译： N，N'-二取代的2-萘甲酰亚胺酰胺是通过醇解将腈转化成新的酰亚胺酯盐中间体，然后用烷基胺处理中间体，得到产物。

53. 发明授权

US4086344A N,15-Didehydro-15-deoxo-3,15-epi(methano(alkylimino))rifamycins and antimicrobial compositions and methods employing them 失效
标题翻译： N，15-脱氢-15-脱氧-3,15-表（亚甲基（烷基亚氨基））利福霉素和使用它们的抗微生物组合物和方法
公开(公告)号：US4086344A
公开(公告)日：1978-04-25
申请号：US722455
申请日：1976-09-13
申请人： James R. McCarthy , Jimmie L. Moore
发明人： James R. McCarthy , Jimmie L. Moore
IPC分类号： C07D498/18 , A61K31/505
CPC分类号： C07D498/18
摘要： N,15-Didehydro-15-deoxo-3,15-epi(methano(alkylimino))rifamycins which can exist in either the quinone or hydroquinone form, are prepared from the corresponding Mannich base derivatives by an acid-catalyzed dehydration reaction.
摘要翻译：可以以醌或氢醌形式存在的N，15-二脱氢-15-脱氧-3,15-表（亚甲基（烷基亚氨基））利福霉素由相应的曼尼希碱衍生物通过酸催化脱水反应制备。

54. 发明授权

US09206141B2 Processes for preparing linezolid 有权
标题翻译：制备利奈唑胺的方法
公开(公告)号：US09206141B2
公开(公告)日：2015-12-08
申请号：US13695211
申请日：2011-04-28
申请人： James R. McCarthy
发明人： James R. McCarthy
IPC分类号： C07D265/30 , C07D263/20
CPC分类号： C07D263/20
摘要： Processes and intermediates for preparing linezolid, and pharmaceutically acceptable salts thereof, are described herein.
摘要翻译：本文描述了制备利奈唑胺的方法和中间体及其药学上可接受的盐。

55. 发明授权

US06974808B2 CRF receptor antagonists and methods relating thereto 有权
标题翻译： CRF受体拮抗剂及其相关方法
公开(公告)号：US06974808B2
公开(公告)日：2005-12-13
申请号：US09995159
申请日：2001-11-27
申请人： James R. McCarthy
发明人： James R. McCarthy
IPC分类号： A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/5025 , A61K31/519 , A61K31/53 , A61P1/04 , A61P1/14 , A61P3/04 , A61P9/08 , A61P9/12 , A61P25/22 , A61P25/24 , A61P27/02 , A61P29/00 , C07D235/08 , C07D471/04 , C07D473/00 , C07D487/04
CPC分类号： C07D471/04 , C07D235/08 , C07D473/00 , C07D487/04
摘要： CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.
摘要翻译：公开了CRF受体拮抗剂，其可用于治疗各种疾病，包括治疗在温血动物（例如中风）中表现出CRF过度分泌的病症。

56. 发明授权

US06531475B1 CRF receptor antagonists and methods relating thereto 有权
标题翻译： CRF受体拮抗剂及其相关方法
公开(公告)号：US06531475B1
公开(公告)日：2003-03-11
申请号：US09574751
申请日：2000-05-18
申请人： Mustapha Haddach , Brian P. Dyck , Charles Q. Huang , Jodie Nelson , Zhiqiang Guo , James R. McCarthy
发明人： Mustapha Haddach , Brian P. Dyck , Charles Q. Huang , Jodie Nelson , Zhiqiang Guo , James R. McCarthy
IPC分类号： C07D47114
CPC分类号： C07D471/16 , C07D487/16
摘要： CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2 and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same
摘要翻译：公开了CRF受体拮抗剂，其可用于治疗各种疾病，包括治疗在温血动物（例如中风）中表现出CRF过度分泌的病症。本发明的CRF受体拮抗剂具有以下结构：包括立体异构体及其药学上可接受的盐，其中n，m，A，B，C，R，R 1，R 2和Ar如本文所定义。还公开了含有CRF受体拮抗剂与药学上可接受的载体的组合物，以及其用途的方法

57. 发明授权

US06482836B1 CRF antagonistic quino- and quinazolines 失效
标题翻译： CRF拮抗喹诺酮和喹唑啉
公开(公告)号：US06482836B1
公开(公告)日：2002-11-19
申请号：US09403393
申请日：1999-10-19
申请人： Charles Huang , Keith M. Wilcoxen , Chen Chen , Mustapha Haddach , James R. McCarthy
发明人： Charles Huang , Keith M. Wilcoxen , Chen Chen , Mustapha Haddach , James R. McCarthy
IPC分类号： A61K314706
CPC分类号： C07D215/233 , C07D215/12 , C07D215/36 , C07D215/42 , C07D239/94 , C07D401/04
摘要： This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is C1-6alkyl, NR6R7, OR6 or SR7; R2 is hydrogen, C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is Ar1 or Het1; R4 and R5 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, cyano, nitro, amino, and mono- or di(C1-6alkyl)amino; R6 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R7 is hydrogen, C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxy-C1-6alkyl or C1-6alkyloxyC1-6alkyl; R6 is C1-8alkyl, mono- or di(C3-6cycloalkyl)-methyl, Ar2CH2, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C1-6alkyl or C1-6alkyloxyC1-6alkyl; and Ar1 and Ar2 are each optionally substituted phenyl; and Het1 is optionally substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).
摘要翻译：本发明涉及包括立体异构体及其药学上可接受的酸加成盐形式的化合物，其中R 1是C 1-6烷基，NR 6 R 7，OR 6或SR 7; R2是氢，C1-6烷基，C1-6烷氧基或C1-6烷硫基; R3是Ar1或Het1; R 4和R 5各自独立地选自氢，卤素，C 1-6烷基，C 1-6烷氧基，三氟甲基，氰基，硝基，氨基和单或二（C 1-6烷基）氨基; R6是氢，C1-6烷基，C1-6烷基磺酰基，C1-6烷基亚磺酰基或C1-6烷硫基; R 7是氢，C 1-8烷基，一或二（C 3-6环烷基）甲基，C 3-6环烷基，C 3-6烯基，羟基C 1-6烷基，C 1-6烷基羰氧基-C 1-6烷基或C 1-6烷氧基C 1-6烷基; R 6是C 1-8烷基，单或二（C 3-6环烷基） - 甲基，Ar 2 CH 2，C 1-6烷氧基C 1-6烷基，羟基C 1-6烷基，C 3-6烯基，噻吩基甲基，呋喃基甲基，C 1-6烷硫基C 1-6烷基，单或二 1-6烷基）氨基C 1-6烷基，二（C 1-6烷基）氨基，C 1-6烷基羰基C 1-6烷基; 或R6和R7与它们所连接的氮原子一起可以形成任选被C 1-6烷基或C 1-6烷氧基C 1-6烷基取代的吡咯烷基，哌啶基，高哌啶基或吗啉基; Ar 1和Ar 2各自为任意取代的苯基; Het1是任选取代的吡啶基; 具有CRF受体拮抗特性; 含有这些化合物作为活性成分的药物组合物; 通过施用有效的治疗来治疗与CRF过度分泌有关的疾病的方法，例如抑郁，焦虑，药物滥用

58. 发明授权

US06469166B2 Thiophenopyrimidines 有权
标题翻译：噻吩并嘧啶
公开(公告)号：US06469166B2
公开(公告)日：2002-10-22
申请号：US09896250
申请日：2001-06-29
申请人： Thomas R. Webb , Chen Chen , James R. McCarthy , Terence J. Moran
发明人： Thomas R. Webb , Chen Chen , James R. McCarthy , Terence J. Moran
IPC分类号： C07D49504
CPC分类号： C07D495/04
摘要： This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO2; R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C1-6alkyloxy-C1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of formula -Alk-O—CO-Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).
摘要翻译：本发明涉及包括立体异构体及其药学上可接受的酸加成盐形式的化合物，其中X是S，SO或SO 2; R1是NR4R5或OR5; R2是C1-6烷基，C1-6烷氧基或C1-6烷硫基; R3是氢，C1-6烷基，C1-6烷基磺酰基，C1-6烷基亚磺酰基或C1-6烷硫基; R4是氢，C1-6烷基，一或二（C3-6环烷基）甲基，C3-6环烷基，C3-6烯基，羟基C1-6烷基，C1-6烷基羰基氧基C 1-6烷基或C 1-6烷氧基C 1-6烷基; R5是C1-6烷基，单或二（C3-6环烷基）甲基，Ar1CH2，C1-6烷氧基-C 1-6烷基，羟基C 1-6烷基，C 3-6烯基，噻吩基甲基，呋喃基甲基，C 1-6烷硫基C 1-6烷基，吗啉基，单或二（C 1-6烷基）氨基C 1-6烷基，二（C 1-6烷基）氨基，C 1-6烷基羰基C 1-6烷基，被咪唑基取代的C 1-6烷基; 或式-Alk-O-CO-Ar1基团; 或R 4和R 5与它们所连接的氮原子一起可以形成任选取代的吡咯烷基，哌啶基，高哌啶基或吗啉基; Ar是苯基，取代的苯基，吡啶基或取代的吡啶基; 具有CRF受体拮抗特性; 含有这些化合物作为活性成分的药物组合物; 通过施用有效量的式（I）化合物来治疗与CRF过度分泌有关的疾病的方法，例如抑郁症，焦虑症，药物滥用。

59. 发明授权

US06218364B1 Fluorinated neurokinin A antagonists 失效
标题翻译：氟化神经激肽A拮抗剂
公开(公告)号：US06218364B1
公开(公告)日：2001-04-17
申请号：US08638407
申请日：1996-04-26
申请人： Scott L. Harbeson , James R. McCarthy
发明人： Scott L. Harbeson , James R. McCarthy
IPC分类号： A61K3800
CPC分类号： C07K5/0207 , A61K38/00 , C07K5/0212 , C07K7/22 , Y10S514/803
摘要： Peptide derivatives which are antagonists of neurokinin A. The derivatives have a modified peptide bond having a reduced amide and a fluorinated alkyl attached to the nitrogen atom of the modified peptide bond. For example, Asp-Ser-Phe-Val-Gly-Leu&PSgr;[CH2N(CH2CF3)]Leu(NH2).
摘要翻译：作为神经激肽A拮抗剂的肽衍生物。该衍生物具有修饰的肽键，其具有还原的酰胺和与修饰的肽键的氮原子连接的氟化烷基。例如，Asp-Ser-Phe-Val-Gly-Leu＆PSgr; [CH2N（CH2CF3）] Leu（NH2）。

60. 发明授权

US5607925A Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides 失效
标题翻译：通过给予2'-卤代亚甲基-2'-脱氧核苷治疗癌症
公开(公告)号：US5607925A
公开(公告)日：1997-03-04
申请号：US333017
申请日：1994-11-01
申请人： Donald P. Matthews , Alan J. Bitonti , Michael L. Edwards , James R. McCarthy
发明人： Donald P. Matthews , Alan J. Bitonti , Michael L. Edwards , James R. McCarthy
IPC分类号： C07H19/06 , C07H19/16 , A61K31/70
CPC分类号： C07H19/06 , C07H19/16
摘要： This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease states.
摘要翻译：本发明涉及某些新的2'-卤代亚甲基，2'-亚乙基和2'-乙炔基胞苷，尿苷和鸟苷衍生物及其组合物，其可用于治疗患有肿瘤或病毒疾病状态的患者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式